Platelet Aggregation Inhibitors Clinical Trial
Official title:
The Influence of CYP2C19 Polymorphism on Antiplatelet Effects and Clinical Outcomes in Non-acute Stroke Patients Treated With Clopidogrel: The Contribution of Genetic Analysis to the Efficacy of Clopidogrel (Cognac) Study
Background:
Clopidogrel, an antiplatelet prodrug, is widely used for prevention of the recurrent
cardiovascular events. CYP2C19 is one of the crucial enzymes for the activation of
clopidogrel. Recent studies, mostly done in cardiovascular patients, showed association of
the CYP2C19 genotypes with recurrent cardiovascular events. However, prospective data on the
impact of the genetic variants in stroke patients are limited.
Methods:
Five hundred and eighteen Japanese non-acute stroke patients treated with clopidogrel were
registered at 14 institutions. Three CYP2C19 variants (CYP2C19*2, *3, *17) were genotyped
and the patients were classified into three clopidogrel metabolizer groups inferred from the
CYP2C19 genotypes: extensive (EM: *1/*1), intermediate (IM: *1/*2 or *1/*3), and poor (PM:
*2/*2, *2/*3, or *3/*3). The CYP2C19*17 carriers were excluded from the analysis. The
antiplatelet effects of clopidogrel were assessed by Adenosine diphosphate (ADP) -induced
platelet aggregation and vasodilator-stimulated phosphoprotein (VASP) phosphorylation,
expressed as VASP index. The endpoint was the composite incidence of stroke, transient
ischemic attack, myocardial infarction, revascularization, other thromboembolic disease, or
cardiovascular death during 2 years of follow-up.
Status | Completed |
Enrollment | 518 |
Est. completion date | October 2015 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Patients who had received long-term clopidogrel therapy (once a day for at least one month) with a minimum one-month interval between enrollment and the last cerebral ischemic or TIA event. - Males and females aged 20 years or older who were prescribed clopidogrel for the secondary prevention of cerebral infarction or transient ischemic attack and who were willing and able to give written informed consent. Exclusion Criteria: - Malignancies - Congenital bleeding tendency - Atrial fibrillation - Concomitant use of an oral anticoagulant agent - a platelet count of < 100 x 109/L or > 450 x 109/L within 3 months of enrollment - Modified rankin scale > 4 |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Cerebral and Cardiovascular Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome of the study was recurrent cardiovascular event (CVEs), including ischemic stroke, transient ischemic attack (TIA), acute myocardial infarction, urgent revascularization, other thromboembolic disease, and cardiovascular death. | Ischemic stroke was defined as a new neurologic deficit of cardiovascular origin lasting at least > 24 hours based on radiological evidence of stroke. TIA was defined as a transient episode of neurologic dysfunction caused by focal brain ischemia and improving within 24 hours. Urgent revascularization was defined as emergent revascularization for unexpected hospitalization. Acute myocardial infarction was defined as myocardial cell necrosis in the setting of ischemic symptoms and electrocardiogram changes (ST segment elevation or depression, development of Q waves) and/or rising specific cardiac biomarkers. Cardiovascular death was defined as death due to stroke, myocardial infarction or documented sudden cardiac death. | Two Years | Yes |
Secondary | Secondary outcome was major bleeding (intracranial haemorrhage, documented retroperitoneal bleed, and any red blood cell transfusion rates or proportion with bleeding associated with a ?2g/dl hemoglobin drop). | Intracranial haemorrhage retroperitoneal bleed were defined on radiological evidence. Proportion with bleeding associated with a ?2g/dl hemoglobin drop was assessed by Blood laboratory test. | two years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
Recruiting |
NCT04796714 -
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
|
Phase 4 | |
Completed |
NCT05278637 -
GM03 - Platelet RNA Signatures of Aspirin
|
Early Phase 1 | |
Recruiting |
NCT03288441 -
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
|
||
Recruiting |
NCT05306951 -
Correct Timing of Head Imaging in Trauma
|
||
Recruiting |
NCT05732701 -
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
|
N/A | |
Recruiting |
NCT05702463 -
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
|
Phase 1 | |
Not yet recruiting |
NCT03862651 -
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)
|
Phase 2 | |
Completed |
NCT01354808 -
ACCEL-LOADING-ACS Study
|
Phase 4 | |
Completed |
NCT00799396 -
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
|
Phase 4 | |
Completed |
NCT00325390 -
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
|
Phase 3 | |
Completed |
NCT04999293 -
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
|
||
Completed |
NCT04328883 -
Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin
|
Phase 1 | |
Completed |
NCT02808767 -
Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction
|
Phase 4 | |
Completed |
NCT00769938 -
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
|
Phase 4 | |
Completed |
NCT03599284 -
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
|
Phase 2 | |
Completed |
NCT03785509 -
The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
|
||
Unknown status |
NCT01103843 -
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
|
N/A | |
Active, not recruiting |
NCT03462498 -
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
|
Phase 4 |